Get to Know Dr. Scott Antonia
After more than two decades at the Moffitt Cancer Center in Tampa, Florida, including seven years as chairman of the Department of Thoracic Oncology, Dr. Scott Antonia joined Duke Cancer Institute. At Moffitt, Antonia spearheaded the Mesothelioma Research and Treatment Center’s creation.
Since his appointment to director of the Duke Cancer Institute Center for Cancer Immunotherapy in February 2019, Antonia has focused on developing an elite immunotherapy program at Duke to improve treatment for malignant mesothelioma and lung cancer.
Antonia also has been credited with advancing collaboration between research scientists and clinical researchers, accelerating therapeutic advances.
He was the lead author of studies that have detailed the effectiveness of novel immunotherapy treatments Imfinzi (durvalumab) and Opdivo for lung cancer. Immunotherapy involves finding more effective ways to use a patient’s immune system in the fight against cancer.
Antonia has vast experience in developing clinical trials that have consistently advanced cancer treatment. His lung cancer research has played a role in setting guidelines adopted and published by the National Comprehensive Cancer Network.
After earning his Ph.D. and medical degree from the University of Connecticut, Antonia completed a residency in internal medicine and a fellowship in medical oncology from Yale University. He also received a post-doctoral fellowship in immunobiology from the Yale University School of Medicine.
Specialties of Dr. Scott Antonia
- Pleural mesothelioma
- Lung cancer
Dr. Scott Antonia’s Experience and Medical Education
- University of Connecticut School of Medicine (M.D.)
- Yale University School of Medicine (Residency and fellowships)
Awards and Certifications for Dr. Scott Antonia
- Researcher of the Year (2018)
- Mentor of the Year (2008)
- Physician of the Year (2005)
Mesothelioma Clinical Trials Under Scott Antonia, M.D.
- Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma.
Publications of Dr. Scott Antonia
- Zheng, H. et al. (2020, August). Development of MEM-288, a dual-transgene armed and conditionally replication-enhanced oncolytic adenovirus with potent systemic antitumor immunity. American Association for Cancer Research.
- Planchard, D. et al. (2020, August). Impact of smoking on outcomes with durvalumab following chemoradiotherapy in unresectable Stage III NSCLC (PACIFIC). American Association for Cancer Research.
- Creelan, B. et al. (2020, August). Durable complete responses to adoptive cell transfer using tumor infiltrating lymphocytes (TIL) in non-small cell lung cancer (NSCLC): A phase I trial. American Association for Cancer Research.
- Naidoo, J. et al. (2020, May 20). Non-pneumonitis immune-mediated adverse events (imAEs) with durvalumab in patients with unresectable stage III NSCLC (PACIFIC). Journal of Clinical Oncology.
- Saltos, A.N. et al. (2020, May 20). Phase II randomized trial of first-line pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC). Journal of Clinical Oncology.
Thank you for your feedback. Would you like to speak with a Patient Advocate?